Literature DB >> 8853758

Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis.

C M Bate1, S M Griffin, P W Keeling, A T Axon, M W Dronfield, R W Chapman, D O'Donoghue, J Calam, J Crowe, R A Mountfords, D A Watts, M D Taylor, P D Richardson.   

Abstract

BACKGROUND: As many as 50% of patients with reflux symptoms have no endoscopic evidence of oesophagitis. This multicentre study was designed to assess symptom relief after omeprazole 20 mg once daily in patients with symptoms typical of gastro-oesophageal reflux disease but without endoscopic evidence of oesophagitis.
METHODS: Patients (n = 209) were randomized in a double-blind study to receive either omeprazole 20 mg once daily (n = 98) or placebo (n = 111) for 4 weeks. Symptoms were assessed at clinic visits and using daily diary cards, with patient-completed questionnaires providing additional data on symptoms and on psychological disturbance.
RESULTS: On completion, symptom relief favoured omeprazole: 57% of patients on omeprazole were free of heartburn (vs. 19% on placebo), 75% were free of regurgitation (47%) and 43% were completely asymptomatic (14%), each with P < 0.0001. Fewer patients in the omeprazole group required alginate/antacid relief medication (P < 0.05). Symptom relief (time to first heartburn-free day) was more rapid with omeprazole (2 vs. 5 days on placebo; P < 0.01). A greater reduction in anxiety occurred in the omeprazole group (P < 0.05).
CONCLUSION: Omeprazole 20 mg once daily is effective in providing relief of the symptoms typical of gastro-oesophageal reflux disease in patients with essentially normal oesophageal mucosa.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8853758     DOI: 10.1046/j.1365-2036.1996.44186000.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  27 in total

1.  An evidence-based appraisal of reflux disease management--the Genval Workshop Report.

Authors: 
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

Review 2.  Functional heartburn: the stimulus, the pain, and the brain.

Authors:  R Fass; G Tougas
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

Review 3.  Endoscopy-negative reflux disease.

Authors:  J P Galmiche; S B des Varannes
Journal:  Curr Gastroenterol Rep       Date:  2001-06

4.  Functional Gastroesophageal Reflux Disease (GERD).

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  2000-08

Review 5.  Assessment of reflux symptom severity: methodological options and their attributes.

Authors:  P Bytzer
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

6.  A poor response to proton pump inhibition is not a contraindication for laparoscopic antireflux surgery for gastro esophageal reflux disease.

Authors:  P M Wilkerson; J Stratford; L Jones; J Sohanpal; M I Booth; T C B Dehn
Journal:  Surg Endosc       Date:  2005-07-14       Impact factor: 4.584

7.  Meta-analysis: the effects of placebo treatment on gastro-oesophageal reflux disease.

Authors:  F Cremonini; D C Ziogas; H Y Chang; E Kokkotou; J M Kelley; L Conboy; T J Kaptchuk; A J Lembo
Journal:  Aliment Pharmacol Ther       Date:  2010-03-26       Impact factor: 8.171

Review 8.  Guide to the use of proton pump inhibitors in adult patients.

Authors:  Vandana Boparai; Jaishree Rajagopalan; George Triadafilopoulos
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease.

Authors:  Naomi Uemura; Hideto Inokuchi; Hiroshi Serizawa; Toshiharu Chikama; Masao Yamauchi; Tomomi Tsuru; Toru Umezu; Toshiro Urata; Nobuo Yurino; Satoshi Tanabe; Tomoharu Yoshida; Susumu Kawamura; Atsushi Murakami; Munemitsu Yamamoto; Tsutomu Chiba
Journal:  J Gastroenterol       Date:  2008-09-20       Impact factor: 7.527

Review 10.  Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs.

Authors:  J Dent; D Armstrong; B Delaney; P Moayyedi; N J Talley; N Vakil
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.